Kezar Life Sciences (NASDAQ:KZR) Earns Neutral Rating from HC Wainwright

Kezar Life Sciences (NASDAQ:KZR)‘s stock had its “neutral” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports.

Other analysts also recently issued research reports about the stock. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th. Wells Fargo & Company cut their price target on Kezar Life Sciences from $20.00 to $11.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th.

Kezar Life Sciences Trading Down 4.6 %

Shares of Kezar Life Sciences stock opened at $7.07 on Monday. Kezar Life Sciences has a fifty-two week low of $5.20 and a fifty-two week high of $11.35. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $7.58 and a two-hundred day simple moving average of $6.77.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.25. Equities research analysts forecast that Kezar Life Sciences will post -6.3 earnings per share for the current year.

Institutional Investors Weigh In On Kezar Life Sciences

Several large investors have recently bought and sold shares of the stock. Mackenzie Financial Corp acquired a new stake in shares of Kezar Life Sciences in the 2nd quarter valued at $35,000. XTX Topco Ltd raised its stake in Kezar Life Sciences by 256.1% in the third quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock valued at $40,000 after buying an additional 37,504 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Kezar Life Sciences in the second quarter valued at $63,000. Geode Capital Management LLC lifted its holdings in Kezar Life Sciences by 15.0% during the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock worth $485,000 after buying an additional 81,678 shares during the last quarter. Finally, Acuitas Investments LLC increased its holdings in shares of Kezar Life Sciences by 42.8% in the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after acquiring an additional 295,956 shares during the last quarter. Hedge funds and other institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.